| Similar Articles |
|---|
 |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.   |
The Motley Fool
August 31, 2010
Brian Orelli |
Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior. |
Searcher
June 2012
Stephanie C. Ardito |
The Medical Digital: How Safe Are the Prescription Drugs we Take? Monitoring Adverse Events and Recalls For general information about prescription and clinical trial drugs, the following websites have been around for a while and have excellent reputations. |
Information Today
October 29, 2015 |
Thomson Reuters Streamlines Healthcare Industry Analysis Thomson Reuters rolled out the Healthcare Intelligence application for Thomson Reuters Eikon to improve workflow for financial professionals. |
AskMen.com
October 30, 2015
Asandra & Palubicki |
Are Erectile Dysfunction Supplements Dangerous? Here's why erectile dysfunction supplements can be extremely dangerous. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
BusinessWeek
May 27, 2010
Michelle Cortez |
Karo Bio's Prescription: Cheaper Drug Approval A Swedish company seeks a lower-cost review for its cholesterol drug. |
The Motley Fool
December 4, 2006
Michael P. Cecil |
Pfizer's Cholesterol-Drug Hopes Crumble In surprising and disappointing news, the pharma's promising new drug fails clinical trials. With Pfizer shares declining because of the bad news, is now a good time to buy? |
Pharmaceutical Executive
January 1, 2009
Amit Agarwal |
Overlooked Opportunities For pharma companies facing a difficult economic climate, pairing diagnostics with therapies offers a powerful incentive: Manufacturers can improve sales by helping physicians find the most appropriate therapeutic option. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
Pharmaceutical Executive
September 1, 2008
Jeffrey S. Aronin |
The Orphan Opportunity The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains |
The Motley Fool
June 25, 2007
Brian Orelli |
Leading the Pack of Follow-On Drug Makers Generic drug maker Dr. Reddy's Laboratories is taking a huge risk to get ahead of the pack, but it's well worth the rewards of being in front of its competitors. Investors, take note. |
Pharmaceutical Executive
October 1, 2011
Jill Wechsler |
At the Helm of Industry As the lead FDA official overseeing the testing and approval of new drugs and biotech therapies for some 20 years, Dr. Janet Woodcock has built a robust and modern drug regulatory system. |
AskMen.com
Richard Stevens |
Participating In Clinical Trials Check out what participating in clinical trials involves and how you can join a study. You may even make some cash in the process. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
Chemistry World
March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
Chemistry World
October 5, 2012
Phhillip Broadwith |
Bayer and Evotec team up on endometriosis Bayer Healthcare and Evotec have agreed to collaborate in their search for drugs for endometriosis, a disease in which cells of the type that normally line the uterus wall grow outside of the womb. |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
Pharmaceutical Executive
September 1, 2006
Patrick Clinton |
From the Editor: Undecided People are buying drugs, because companies are selling drugs. Interfere with the selling process, and people won't buy as many drugs. |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. |
Information Today
June 3, 2013 |
Wolters Kluwer Health Partners With Amirsys on Two Databases Wolters Kluwer Health and Amirsys, Inc., international providers of healthcare solutions, added two new clinical reference databases to their portfolios in late May: the Amirsys Pathology Reference Center and the Amirsys Anatomy Reference Center. |
The Motley Fool
July 28, 2010
Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
Chemistry World
August 27, 2015
Phillip Broadwith |
Drugs in a class of their own In the last month, three drugs in new therapeutic classes have been approved for cardiovascular diseases. |
Chemistry World
September 11, 2012
Maria Burke |
Orphan drugs set for 'tremendous growth' A new report by Thomson Reuters offers clear confirmation that developing drugs for rare, or orphan, diseases is economically attractive, despite the smaller patient pool. |
Chemistry World
March 27, 2013
Eugene Gerden |
Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. |
Reason
Aug/Sep 2001
Jacob Sullum |
Through the Nose An FDA advisory committee has voted overwhelmingly to recommend over-the-counter status for Claritin, Allegra, and Zyrtec, three popular prescription allergy drugs. But the drugs' manufacturers are opposing a switch, fearing that it could hurt their profits... |
BusinessWeek
April 18, 2005 |
Making Those Pills Safe For Kids Few medicines get tested on children. Dr. Donald Mattison is pushing to change that. |
The Motley Fool
August 15, 2007
Mary Dalrymple |
Drug Costs Giving You a Headache? If you want to cut your prescription drug costs, you can do more than just switch to generic brands. Shop around and ask questions. It's your health, and it's your money. |
The Motley Fool
September 8, 2004
Charly Travers |
Will a Clinical Trial Database Help Investors? While this development is certainly good news for patients and physicians, the impact on investors may be minimal, depending upon the type of data that will be released. |
ONLINE
Jul/Aug 2012
Sarah L. Elichko |
Triage, Treat, Release: Finding Medical Information Using MedlinePlus and PubMed Emergency rooms have instituted a protocol called Triage, Treat, Release to care for patients presenting with minor injuries. It's also an apt metaphor for librarians helping patrons to find information, whether the reference desk is physical or virtual. |
The Motley Fool
January 12, 2010
Dayana Yochim |
6 Ways to Score Cheap(er) Drugs Stop overpaying for the pills you have to pop with these simple ways to trim your prescription-drug tab. |
Pharmaceutical Executive
October 1, 2010 |
Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector. |
The Motley Fool
February 25, 2010
Brian Orelli |
An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies. |
BusinessWeek
March 11, 2010
Ellen Gibson |
The Quest to Boost Good Cholesterol Cleveland Clinic's Steven Nissen is again pursuing a drug that will attack plaque by raising HDL. |
The Motley Fool
December 30, 2010
Brian Orelli |
This NICE Deal Could Foreshadow 2011 Value-based pricing is coming. The only way to encourage lower drug costs is to get the end user to pay the cost directly. |
CIO
September 26, 2013
Stephanie Overby |
Big Data Project Cuts Prescription Costs Express Scripts analytics portal helps doctors prescribe more cost-effective medicines. |
BusinessWeek
May 23, 2005
Carol Marie Cropper |
Counter Intelligence Nonprescription drugs can often be just as strong as prescription drugs; in fact, many of them used to be just that. So, to use over-the-counter drugs safely, educate yourself about dosage, possible interactions, and even ingredients. |
Chemistry World
October 8, 2010
Sarah Houlton |
U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness. |
The Motley Fool
January 28, 2010
Brian Orelli |
Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds. |
Chemistry World
March 25, 2010
Rebecca Trager |
Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'. |
Pharmaceutical Executive
July 30, 2007
Peter Pitts |
Opinion: Fewer Cents, More Sense Our healthcare system may be broken, but playing the blame game is not going to fix it. Remember that disease - not Big Pharma - is the enemy. |
The Motley Fool
June 6, 2006
Brian Lawler |
Exelixis' Continued Excellence The company reported preliminary phase 1 results for three of its lead compounds. Until investors see the results from phase 2 trials, they should chalk Exelixis up as a promising young biotech company whose successes they will patiently cheer for from the sidelines. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
Bio-IT World
November 14, 2003
John Dodge |
Pfizer's Man with the R&D Plan As Pfizer senior vice president, science and technology, Peter B. Corr oversees $7.1 billion in annual research and development spending, the biggest private R&D budget in the world. In this interview, Corr talks about IT, clinical trials, and his $7-billion budget. |
The Motley Fool
May 14, 2007
Mike Havrilla |
A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs. |
Pharmaceutical Executive
March 1, 2011
Jerry Coamey |
Engage the Physician! New research shows that gauging the mind of the clinician is crucial to timely uptake of the new diagnostic tools offered by the genomic revolution |
